Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose nearly 7%, ESMO data update imminent, executives continued to increase their holdings, showing confidence in development

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose nearly 7%. As of press release, it had risen 6.81% to HK$5.49, with a turnover of HK$35.1891 million.

According to the news, the latest clinical data of CS2009 (PD-1/VEGF/CTLA-4 three-specific antibody), the core asset of Cornerstone Pharmaceuticals, will be disclosed in the form of two quick oral reports at the European Society of Medical Oncology (ESMO) annual meeting to be held in October 2026. In addition, Yang Jianxin, CEO of the company, CEO of R&D and executive director, purchased a total of 496,000 shares of the company on the open market with personal capital from September 17 to 22, at a total cost of over HK$2.7 million.

According to reports, since becoming CEO in August 2022, Dr. Yang Jianxin has purchased more than 14.21 million shares of the company on the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.